Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00151528 · ClinicalTrials.gov registry record · Phase 3

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 3
Development phase
428
Enrollment target

NCT00151528 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 428 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00151528, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 3
Development phase
428 participants
Enrollment target

Study Summary

The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.

Interventions

  • DRUG Pregabalin

Trial Details

FieldValue
Enrollment Target 428 participants
Start Date 2005-01
Est. Completion 2006-06
Phase Phase 3

What the Registry Record Tells You About NCT00151528

The ClinicalTrials.gov registry entry for NCT00151528 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Pregabalin is the first listed.

NCT00151528 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00151528 about?

NCT00151528 is a clinical study titled "An Open-Label Trial of Pregabalin in Patients With Fibromyalgia". The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.

What is the current status of trial NCT00151528?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 428 participants. The study started on 2005-01. Estimated completion is 2006-06.

What interventions are being tested in trial NCT00151528?

The interventions under investigation include: Pregabalin (DRUG).

Who is sponsoring clinical trial NCT00151528?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.